Skip to content

Trial Summary

A phase III, randomised, open-label, controlled, multi-centre, global study of first-line durvalumab in combination with standard of care chemotherapy and durvalumab in combination with tremelimumab and standard of care chemotherapy in patients with unresectable Urothelial Cancer.

Acronym:

NILE

ACTRN/NCT /ethics:

NCT03682068

Scientific title:

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

Sponsor / Cooperative group:

AstraZeneca

Trial & Patient Characteristics

Cancer TypeBladder
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream Urothelial Cancer
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2018-09-27
Anticipated End Date2024-03-29

Participating Hospitals

HospitalLyell McEwin Hospital
Clinical Trial CoordinatorAndy Phay
Emailandy.phay@sa.gov.au
Phone08 8282 0833
Principal InvestigatorDr Christopher Hocking
Recruitment StatusRecruiting